Oppenheimer lowered its price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

BofA/Merrill Lynch Downgrades Seres Therapeutics (MCRB) to UnderperformAugust 3, 2018 6:10 AM Form 10-Q Seres Therapeutics, Inc. For: Jun 30August 2, 2018 11:38 AM Seres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues MissAugust 2, 2018 7:20 AM Form 8-K Seres Therapeutics, Inc. For: Aug 02August 2, 2018 7:09 AM Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational UpdatesAugust 2, 2018 7:00 AM